PTAFR and non-small cell lung carcinoma: To determine the effects of PAFR activation and miR-149-5p overexpression on the efficacy of targeted therapies in NSCLC cell lines, we first optimized the dose- and time-dependent cytotoxic responses of erlotinib and gefitinib using A549 and H1299 cell lines.